DRTX
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois.
Best luck.
Best luck.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.